Clopidogrel hyporesponsiveness and the FDA boxed warning: Detection and management of patients with genetic polymorphisms

American Journal of Health-System Pharmacy

Volumn 68, Issue 6, 2011, Pages 529-532

  Perry, Elizabeth ^a  

^a UNIVERSITY OF LOUISIANA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYTOCHROME P450 2C19; PRASUGREL;

ACUTE CORONARY SYNDROME; ALLELE; BLOOD CLOT LYSIS; BLOOD CLOTTING PARAMETERS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG METABOLISM; EXON; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; NOTE; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE; UNSTABLE ANGINA PECTORIS;

EID: 79956010769     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100422     Document Type: Note

References (21)

1. Food and Drug Administration. FDA drug safety communication: reduced effectiveness of Plavix (clopidogrel) in patients who are poor metabolizers of the drug. www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/ucm203888.htm (accessed 2010 May 15).
2. Brandt JT, Close SL, Iturria SJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel not prasugrel. J Thromb Haemost. 2007; 5:2429-36. (Pubitemid 350154353)
3. Plavix (clopidogrel) package insert. Bridgewater, NJ: Bristol-Myers Squibb/ Sanofi Pharmaceuticals Partnership; 2010.
4. Hulot JS, Bura A, Villard E et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood. 2006; 108:2244-7. (Pubitemid 44497506)
5. Trenk D, Hochholzer W, Fromm MF et al. Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare metal stents. J Am Coll Card. 2008; 51:1925-34. (Pubitemid 351636443)
6. Hochholzer W, Trenk D, Besthorn HP et al. Impact of the degree of perinterventional platelet inhibition after loading with clopidogrel of early clinical outcome of elective coronary stent placement. J Am Coll Cardiol. 2007; 48:1742-50. (Pubitemid 44648629)
7. Xie HG, Kim RB, Wood AJ et al. Molecular basis of ethnic differences in drug disposition and response. Annu Rev Pharmacol Toxicol. 2001; 41:815-50. (Pubitemid 32385908)
8. Sim SC, Risinger C, Dahl ML et al. A common novel CYP2C19 gene variant causes ultrarapid drug metabolism relevant for the drug response to proton pump inhibitors and antidepressants. Clin Pharmacol Ther. 2006; 79:103-13. (Pubitemid 43069582)
9. Collet JP, Hulot JS, Pena A et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet. 2009; 373:309-17.
10. Mega JL, Close SL, Wiviott SD et al. Cytochrome P-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009; 360:354-62.
11. Wiviott SD, Antman EM, Gibson CM et al. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel - Thrombolysis in Myocardial Infarction 38 (TRITON-TIMI 38). Am Heart J. 2006; 152:627-35. (Pubitemid 44396884)
12. Yusuf S, Zhao F, Mehta SR et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494-502. (Pubitemid 32758501)
13. Lemesle G, Delhaye C, Sudre A et al. Impact of high loading and maintenance dose of clopidogrel within the first 14 days after percutaneous intervention on patient outcomes. Am Heart J. 2009; 157:375-82.
14. Montalescot G, Sideris G, Meuleman C et al. A randomized comparison of high clopidogrel loading dose in patients with non-ST-segment elevation acute coronary syndromes. J Am Coll Card. 2006; 48:931-8.
15. Patti G, Colonna G, Pasceri V et al. Randomized trial of high loading dose of clopidogrel for reduction of preprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet therapy for Reduction of Myocardial Damage during Angioplasty) study. Circulation. 2005; 111:2090-106.
16. Hughes S. GRAVITAS: no benefit of doubling dose in clopidogrel nonresponders. www.theheart.org (accessed 2010 Dec 15).
17. Wiviott SD, Braunwald E, McCabe C et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007; 357:2001-15. (Pubitemid 350106708)
18. Wiviott SD, Trenk D, Frelinger AL et al. Prasugrel compared with high loadingand maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention. Circulation. 2007; 116:2923-32.
19. Quest Diagnostics. Accutype CP Clopidogrel 2C19 Genotype - test highlight. http://mylabisquest.com/hcp/intguide/jsp/showintguidepage. jsp?fn= Cardiovascular/TH-Clopidogrel-CYP2C19.htm (accessed 2010 May 15).
20. Accumetrics. VerifyNow P2Y12 test. www.accumet r ics. com/products/ vnp2y12.aspx (accessed 2010 Jun 11).
21. Breet NJ, Werkum JW, Bouman HJ et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA. 2010; 303:754-62.